{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:20:55Z","timestamp":1790738455595,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"crossref","award":["2011-0019397"],"award-info":[{"award-number":["2011-0019397"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Korean government","award":["DRC-15-01-KRICT"],"award-info":[{"award-number":["DRC-15-01-KRICT"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ejphar.2017.02.003","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T15:17:32Z","timestamp":1486135052000},"page":"94-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["A novel urotensin II receptor antagonist, KR-36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure"],"prefix":"10.1016","volume":"799","author":[{"given":"Kwang-Seok","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Yang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae Jo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Kil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Won","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2017.02.003_bib1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2407-10-105","article-title":"Long-term survival of cancer patients compared to heart failure and stroke: a systematic review","volume":"10","author":"Askoxylakis","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejphar.2017.02.003_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/01.HYP.28.1.42","article-title":"Orthostatic hypertension due to vascular adrenergic hypersensitivity","volume":"28","author":"Benowitz","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2017.02.003_bib3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11906-006-0026-7","article-title":"Urotensin-II and cardiovascular diseases","volume":"8","author":"Bousette","year":"2006","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ejphar.2017.02.003_bib4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.yjmcc.2006.05.008","article-title":"Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation","volume":"41","author":"Bousette","year":"2006","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ejphar.2017.02.003_bib5","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1016\/j.peptides.2006.06.011","article-title":"Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease","volume":"27","author":"Bousette","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2017.02.003_bib6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/187152508783955024","article-title":"Non peptidic urotensin II antagonists: perspectives for a new class of drugs","volume":"6","author":"Cosenzi","year":"2008","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"10.1016\/j.ejphar.2017.02.003_bib7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/CIRCRESAHA.110.226803","article-title":"Interrelationship between cardiac hypertrophy, heart failure, and chronic kidney disease: endoplasmic reticulum stress as a mediator of pathogenesis","volume":"108","author":"Dickhout","year":"2011","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2017.02.003_bib8","first-page":"2388","volume":"29","author":"Dickstein","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2017.02.003_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1471-4892(03)00012-2","article-title":"Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'","volume":"3","author":"Douglas","year":"2003","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.02.003_bib10","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/S0140-6736(02)08831-1","article-title":"Congestive heart failure and expression of myocardial urotensin II","volume":"359","author":"Douglas","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2017.02.003_bib11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00395-011-0163-2","article-title":"EGFR trans-activation by urotensin II receptor is mediated by \u03b2-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy","volume":"106","author":"Esposito","year":"2011","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.ejphar.2017.02.003_bib12","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1161\/CIR.0b013e318282ab8f","article-title":"Heart disease and stroke statistics-\u22122013 update: a report from the American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2017.02.003_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00003495-198631020-00004","article-title":"Serotonin and the vascular system. Role in health and disease, and implications for therapy","volume":"31","author":"Houston","year":"1986","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2017.02.003_bib14","doi-asserted-by":"crossref","unstructured":"Hunt, S.A., Abraham, W.T., Chin, M.H., Feldman, A.M., Francis, G.S., Ganiats, T.G., Jessup, M., Konstam, M.A., Mancini, D.M., Michl, K., Oates, J.A., Rahko, P.S., Silver, M.A., Stevenson, L.W., Yancy, C.W., 2009. American College of Cardiology Foundation and American Heart Association, 2009\u00a0Focused update incorporated into the ACC\/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol. 53, pp. e1\u2013e90.","DOI":"10.1016\/j.jacc.2008.11.013"},{"key":"10.1016\/j.ejphar.2017.02.003_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)70151-3","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2017.02.003_bib16","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.peptides.2010.04.026","article-title":"Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy","volume":"31","author":"Kompa","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2017.02.003_bib17","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa020265","article-title":"Long-term trends in the incidence of and survival with heart failure","volume":"347","author":"Levy","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2017.02.003_bib18","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1016\/j.bmcl.2014.09.089","article-title":"Synthesis and SAR of thieno[3,2-b]pyridinyl urea derivatives as urotensin-II receptor antagonists","volume":"24","author":"Lim","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2017.02.003_bib19","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.peptides.2007.08.024","article-title":"Urotensin II and atherosclerosis","volume":"29","author":"Loirand","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2017.02.003_bib20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/sj.bjp.0704924","article-title":"Is urotensin-II the new endothelin?","volume":"137","author":"Maguire","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.02.003_bib21","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1038\/sj.jhh.1000987","article-title":"Dopamine: a role in the pathogenesis and treatment of hypertension","volume":"14","author":"Murphy","year":"2000","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ejphar.2017.02.003_bib22","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1111\/bph.13082","article-title":"The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy","volume":"172","author":"Oh","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.02.003_bib23","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1210\/me.2003-0309","article-title":"Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases","volume":"18","author":"Onan","year":"2004","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.ejphar.2017.02.003_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/CIRCHEARTFAILURE.107.748343","article-title":"Direct inotropic effects of exogenous and endogenous urotensin-II: divergent actions in failing and nonfailing human myocardium","volume":"2","author":"Quaile","year":"2009","journal-title":"Circ. Heart Fail"},{"key":"10.1016\/j.ejphar.2017.02.003_bib25","doi-asserted-by":"crossref","first-page":"R1156","DOI":"10.1152\/ajpregu.00706.2009","article-title":"Role of urotensin II in health and disease","volume":"298","author":"Ross","year":"2010","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.ejphar.2017.02.003_bib26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fphar.2011.00038","article-title":"Potential clinical implications of the urotensin II receptor antagonists","volume":"2","author":"Tsoukas","year":"2011","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.02.003_bib27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.RES.0000084382.64418.BC","article-title":"Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy","volume":"93","author":"Tzanidis","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2017.02.003_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1745-7254.2007.00485.x","article-title":"Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol","volume":"28","author":"Zhang","year":"2007","journal-title":"Acta Pharmacol. Sin."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917300699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917300699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T12:52:45Z","timestamp":1536065565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299917300699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":28,"alternative-id":["S0014299917300699"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.02.003","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel urotensin II receptor antagonist, KR-36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}